The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC.
The study is being conducted to evaluate the efficacy and safety of SHR-1316 in combination with chemo-radiotherapy in patients with LS-SCLC.
Small-cell Lung Cancer
DRUG: SHR-1316; Carboplatin; Etoposide；Radiotherapy|DRUG: Palcebo; Carboplatin; Etoposide；Radiotherapy
OS, Overall Survival, up to 36 months
The study is being conducted to evaluate the efficacy and safety of SHR-1316 in combination with chemo-radiotherapy in patients with LS-SCLC.